• <u id="fhy68"><form id="fhy68"></form></u>

        <style id="fhy68"></style>
        1. <blockquote id="fhy68"></blockquote>

          1. 日日摸夜夜爽无码区,国产精品久久久久影视不卡,国产亚洲视频在线观看,国产熟女在线,久久麻豆精亚洲av品国产精品,在线国产69自拍视频,欧美日韩亚洲精品综合乱在线,免费AV人体片在线观看
            Cell Reports Medicine
            收藏雜志
            • 數(shù)據(jù)庫(kù)收錄SCIE
            • 創(chuàng)刊年份2020年
            • 年發(fā)文量305

            Cell Reports Medicine

            期刊中文名:細(xì)胞醫(yī)學(xué)報(bào)道ISSN:2666-3791E-ISSN:2666-3791

            該雜志國(guó)際簡(jiǎn)稱:Cell Rep Med,是由出版商Elsevier出版的一本致力于發(fā)布醫(yī)學(xué)研究新成果的的專業(yè)學(xué)術(shù)期刊。該雜志以MEDICINE, RESEARCH & EXPERIMENTAL研究為重點(diǎn),主要發(fā)表刊登有創(chuàng)見(jiàn)的學(xué)術(shù)論文文章、行業(yè)最新科研成果,扼要報(bào)道階段性研究成果和重要研究工作的最新進(jìn)展,選載對(duì)學(xué)科發(fā)展起指導(dǎo)作用的綜述與專論,促進(jìn)學(xué)術(shù)發(fā)展,為廣大讀者服務(wù)。該刊是一本國(guó)際優(yōu)秀雜志,在國(guó)際上有很高的學(xué)術(shù)影響力。

            基本信息:
            期刊簡(jiǎn)稱:Cell Rep Med
            是否OA:開放
            是否預(yù)警:
            Gold OA文章占比:93.57%
            出版信息:
            出版地區(qū):United States
            出版周期:Monthly
            出版語(yǔ)言:English
            出版商:Elsevier
            評(píng)價(jià)信息:
            中科院分區(qū):1區(qū)
            JCR分區(qū):Q1
            影響因子:11.7
            CiteScore:15
            雜志介紹 中科院JCR分區(qū) JCR分區(qū) CiteScore 投稿經(jīng)驗(yàn)

            雜志介紹

            Cell Reports Medicine雜志介紹

            《Cell Reports Medicine》是一本以English為主的開放獲取國(guó)際優(yōu)秀期刊,中文名稱細(xì)胞醫(yī)學(xué)報(bào)道,本刊主要出版、報(bào)道醫(yī)學(xué)-MEDICINE, RESEARCH & EXPERIMENTAL領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果,介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展,探討行業(yè)發(fā)展的思路和方法,以促進(jìn)學(xué)術(shù)信息交流,提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用,也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為11.7,最新CiteScore 指數(shù)為15。

            本刊近期中國(guó)學(xué)者發(fā)表的論文主要有:

            • Current understanding of the intratumoral microbiome in various tumors

              Author: Xue, Chen; Chu, Qingfei; Zheng, Qiuxian; Yuan, Xin; Su, Yuanshuai; Bao, Zhengyi; Lu, Juan; Li, Lanjuan

            • Inherited mutations in Chinese patients with upper tract urothelial carcinoma

              Author: Wu, Junlong; Jin, Shengming; Gu, Chengyuan; Wei, Yu; Zhu, Yao; Necchi, Andrea; Shariat, Shahrokh F.; Pan, Jian; Gan, Hualei; Dai, Bo; Zhang, Hailiang; Shi, Guohai; Zhu, Yu; Shen, Yijun; Zhu, Yiping; Ye, Dingwei

            • Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases

              Author: Guo, Jiawei; Wang, Fuxiao; Hu, Yan; Luo, Ying; Wei, Yan; Xu, Ke; Zhang, Hao; Liu, Han; Bo, Lumin; Lv, Shunli; Sheng, Shihao; Zhuang, Xinchen; Zhang, Tao; Xu, Can; Chen, Xiao; Su, Jiacan

            • Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET

              Author: Zhang, Qilin; Yao, Boyuan; Long, Xin; Chen, Zhengyuan; He, Min; Wu, Yue; Qiao, Nidan; Ma, Zengyi; Ye, Zhao; Zhang, Yichao; Yao, Shun; Wang, Ye; Cheng, Haixia; Chen, Hong; Ye, Hongying; Wang, Yongfei; Li, Yimin; Chen, Jianhua; Zhang, Zhaoyun; Guo, Fan; Zhao, Yao

            英文介紹

            Cell Reports Medicine雜志英文介紹

            Cell Reports Medicine is a premium open-access journal from Cell Press publishing cutting-edge research in translational and clinical biomedical sciences that inform and influence human health and medicine.

            The content published in Cell Reports Medicine reaches a broad range of scientists and clinicians across the spectrum of medical disciplines, ensuring that your work will be both visible and accessible. The journal publishes original research that ranges from exciting concepts in human biology, health, and disease to all phases of clinical work. We encourage submissions featuring innovative ideas that open up new directions in clinical research and practice, as well as studies that provide critical information that enriches our understanding of current standards of care in diagnosis, treatment, and prognosis. This includes, but is not limited to, translational studies, clinical trials in all areas of medicine including long-term trial follow-ups as well as work in genomics, biomarker discovery, and developments in technology that contribute to diagnostics, treatment, and healthcare. Studies based on vertebrate model organisms also fall within the scope of the journal, provided that the results are directly relevant to human health and disease.

            Like our sister journal Cell Reports, we will consider impactful, single-point papers called reports, in addition to longer articles. Large datasets, techniques, and tools for the community can also be considered under the article format. We will also publish reviews covering recent literature in emerging and active fields.

            The professional in-house scientific editors at Cell Reports Medicine work closely with authors, reviewers, and the journal's editorial board to ensure exemplary editorial process, fair and robust peer review, and rapid dissemination and communication of your research.

            中科院SCI分區(qū)

            Cell Reports Medicine雜志中科院分區(qū)信息

            2023年12月升級(jí)版
            綜述:
            TOP期刊:
            大類:醫(yī)學(xué) 1區(qū)
            小類:

            MEDICINE, RESEARCH & EXPERIMENTAL
            醫(yī)學(xué):研究與實(shí)驗(yàn) 1區(qū)

            CELL BIOLOGY
            細(xì)胞生物學(xué) 2區(qū)

            2022年12月升級(jí)版
            綜述:
            TOP期刊:
            大類:醫(yī)學(xué) 1區(qū)
            小類:

            MEDICINE, RESEARCH & EXPERIMENTAL
            醫(yī)學(xué):研究與實(shí)驗(yàn) 1區(qū)

            CELL BIOLOGY
            細(xì)胞生物學(xué) 2區(qū)

            中科院SCI分區(qū):是中國(guó)科學(xué)院文獻(xiàn)情報(bào)中心科學(xué)計(jì)量中心的科學(xué)研究成果。期刊分區(qū)表自2004年開始發(fā)布,延續(xù)至今;2019年推出升級(jí)版,實(shí)現(xiàn)基礎(chǔ)版、升級(jí)版并存過(guò)渡,2022年只發(fā)布升級(jí)版,期刊分區(qū)表數(shù)據(jù)每年底發(fā)布。 中科院分區(qū)為4個(gè)區(qū)。中科院分區(qū)采用刊物前3年影響因子平均值進(jìn)行分區(qū),即前5%為該類1區(qū),6%~20%為2區(qū)、21%~50%為3區(qū),其余的為4區(qū)。1區(qū)和2區(qū)雜志很少,雜志質(zhì)量相對(duì)也高,基本都是本領(lǐng)域的頂級(jí)期刊。

            JCR分區(qū)(2023-2024年最新版)

            Cell Reports Medicine雜志 JCR分區(qū)信息

            按JIF指標(biāo)學(xué)科分區(qū)
            學(xué)科:CELL BIOLOGY
            收錄子集:SCIE
            分區(qū):Q1
            排名:22 / 205
            百分位:

            89.5%

            學(xué)科:MEDICINE, RESEARCH & EXPERIMENTAL
            收錄子集:SCIE
            分區(qū):Q1
            排名:10 / 189
            百分位:

            95%

            按JCI指標(biāo)學(xué)科分區(qū)
            學(xué)科:CELL BIOLOGY
            收錄子集:SCIE
            分區(qū):Q1
            排名:14 / 205
            百分位:

            93.41%

            學(xué)科:MEDICINE, RESEARCH & EXPERIMENTAL
            收錄子集:SCIE
            分區(qū):Q1
            排名:8 / 189
            百分位:

            96.03%

            JCR分區(qū):JCR分區(qū)來(lái)自科睿唯安公司,JCR是一個(gè)獨(dú)特的多學(xué)科期刊評(píng)價(jià)工具,為唯一提供基于引文數(shù)據(jù)的統(tǒng)計(jì)信息的期刊評(píng)價(jià)資源。每年發(fā)布的JCR分區(qū),設(shè)置了254個(gè)具體學(xué)科。JCR分區(qū)根據(jù)每個(gè)學(xué)科分類按照期刊當(dāng)年的影響因子高低將期刊平均分為4個(gè)區(qū),分別為Q1、Q2、Q3和Q4,各占25%。JCR分區(qū)中期刊的數(shù)量是均勻分為四個(gè)部分的。

            CiteScore 評(píng)價(jià)數(shù)據(jù)(2024年最新版)

            Cell Reports Medicine雜志CiteScore 評(píng)價(jià)數(shù)據(jù)

            • CiteScore 值:15
            • SJR:4.276
            • SNIP:1.664
            學(xué)科類別 分區(qū) 排名 百分位
            大類:Medicine 小類:General Medicine Q1 25 / 636

            96%

            大類:Medicine 小類:General Biochemistry, Genetics and Molecular Biology Q1 18 / 221

            92%

            歷年影響因子和期刊自引率

            投稿經(jīng)驗(yàn)

            Cell Reports Medicine雜志投稿經(jīng)驗(yàn)

            該雜志是一本國(guó)際頂級(jí)雜志,在醫(yī)學(xué)-MEDICINE, RESEARCH & EXPERIMENTAL學(xué)科領(lǐng)域中屬于核心刊物,是能夠綜合反映該學(xué)科領(lǐng)域當(dāng)前最高發(fā)展水平的學(xué)術(shù)期刊。在國(guó)際上有很高的學(xué)術(shù)影響力,行業(yè)關(guān)注度很高,已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄,該雜志在MEDICINE, RESEARCH & EXPERIMENTAL綜合專業(yè)領(lǐng)域?qū)I(yè)度認(rèn)可很高,對(duì)稿件內(nèi)容的創(chuàng)新性和學(xué)術(shù)性要求非常高,作為一本國(guó)際頂級(jí)雜志,一般投稿過(guò)審時(shí)間都較長(zhǎng),投稿過(guò)審時(shí)間平均約Time to desk decision: 6.6 days; Publication time: 3.31 weeks 17 Weeks ,如果想投稿該刊要做好時(shí)間安排。版面費(fèi)不祥。該雜志近兩年未被列入預(yù)警名單,建議您投稿。如您想了解更多投稿政策及投稿方案,請(qǐng)咨詢客服。

            免責(zé)聲明

            若用戶需要出版服務(wù),請(qǐng)聯(lián)系出版商:ELSEVIER, RADARWEG 29, AMSTERDAM, Netherlands, 1043 NX。

            主站蜘蛛池模板: 一二三四日本高清社区5| 青草视频在线观看视频| 老司机性色福利精品视频| 亚洲乱码一区av春药高潮| 首页 图区 国产 亚洲 欧美| 亚洲欧美日韩成人高清在线一区| 欧美亚洲国产一区二区三区| 国产av综合色高清自拍| 久久无码一区二区三区| 日本真人做爰免费的视频| 67194成是人免费无码| 久久久综合九色综合88| 影音先锋资源在线| 欧洲中文字幕国产精品| 久久精品国产亚洲av麻豆小说| 久久精品国产主播一区二区| 亚洲中文无码一区| 狼狼狼色精品视频在线播放| 国产在线精品一区二区不卡麻豆| 熟女人妇 成熟妇女系列视频| 亚洲国产精品区一区二区| 精品人妻二区中文字幕| 国产精品免费看久久久青青| 亚洲成人一区二区AV在线| 在线精品国产大象香蕉网| 亚洲第一综合天堂另类专 | 色丁香一区二区黑人巨大| 亚洲毛片不卡av在线播放一区| 成年午夜视频免费观看视频| 尤物视频网站| 无码国产欧美一区二区三区不卡| 国产一区二区三区精美视频| 蜜桃AV在线| 欧美国产激情18| 91亚洲一区| 国产高清在线精品一区免费 | 国产蜜臀久久av一区二区| 欧美丰满熟妇bbbbbb| 国产成人av大片大片| 天天躁日日躁狠狠躁伊人| 伊人视屏|